ZNTL - Zentalis Pharmaceuticals GAAP EPS of -$1.31 misses by $0.10

Zentalis Pharmaceuticals press release (NASDAQ:ZNTL): Q1 GAAP EPS of -$1.31 misses by $0.10. The company believes that its existing cash, cash equivalents and marketable securities of 4289.4M as of March 31, 2022, together with approximately $24.7M of net proceeds from the April 2022 Pfizer equity investment, prioritization of the clinical development of ZN-c3 and ZN-d5, and budget reallocation, will be sufficient to fund its operating expenses and capital expenditures requirements into the first quarter of 2024.

For further details see:

Zentalis Pharmaceuticals GAAP EPS of -$1.31 misses by $0.10